Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRT for Oligometastatic NSCLC After 3rd Gen EGFR-TKIs
NCT04764214Phase 2Completed
- Sponsor
- Fudan University
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Fudan University. Primary endpoint: Progression Free Survival at 2 years. Started Mar 2021; status: completed.
Beyond the preview
Go deeper on NCT04764214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764214.